

The following slides were used in connection with a presentation to employees on October 10, 2014:



Endo Town Hall Fall 2014

**Rajiv De Silva
President and Chief Executive Officer**



Additional Information

ADDITIONAL INFORMATION

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc. ("Auxilium"). In furtherance of this proposed transaction, Endo and Auxilium intend to file one or more registration statements, prospectuses, proxy statements or other documents with the U.S. Securities and Exchange Commission ("SEC"). This communication is not a substitute for any registration statement, prospectus, proxy statement or other document Endo and/or Auxilium file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF AUXILIUM ARE URGED TO READ THE REGISTRATION STATEMENT, PROSPECTUS, PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive proxy statement (when available) will be mailed to stockholders of Auxilium. Investors and security holders are able to obtain free copies of these documents (when available) and other documents filed with the SEC by Endo through the web site maintained by the SEC at <http://www.sec.gov>.

CERTAIN INFORMATION REGARDING PARTICIPANTS

Endo and Auxilium and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Auxilium stockholders with respect to the proposed transaction under the rules of the SEC. Security holders may obtain information regarding the names and interests of Endo's directors and executive officers in Endo Health Solutions Inc.'s ("EHSI") Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 3, 2014, and Endo's proxy statement for the 2014 Annual General Meeting of Shareholders, which was filed with the SEC on April 29, 2014. Security holders may obtain information regarding the names and interests of Auxilium's directors and executive officers in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 28, 2014, Auxilium's proxy statement for the 2014 Annual Meeting of Stockholders, which was filed with the SEC on April 10, 2014, and the materials filed with the SEC in connection with the proposed transaction. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.

All trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of their respective owners. **Novartis**, **Testin**, **TESTOPEL**, **STENDRA**, **ede**, **Osborn**, **ErecAid**, **STRIAN**, **Theo24**, **Sempre**, **D**, **dilatrat**, **SR** and **robaxin** and the related logos are the property of Auxilium. All other trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of Endo.



Forward-Looking Statements

This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. These forward-looking statements include, but are not limited to, statements regarding the proposed transaction, the financing of the proposed transaction, Endo's and Auxilium's expected future performance (including expected results of operations and financial guidance), and the combined company's future financial condition, operating results, strategy and plans. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's and Auxilium's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Although Endo and Auxilium believe that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this communication. Investors should note that many factors, as more fully described in the documents filed by Endo with the SEC and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR") and by Auxilium with the SEC (including under the caption "Risk Factors" in EHSI Form 10-K and Endo's Form 10-Q and Form 8-K filings, and in Auxilium's 10K, 10-Q and 8-K filings, as applicable, and as otherwise enumerated herein or therein, could affect future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in this communication. Important factors that, individually or in the aggregate, could cause actual results to differ materially from expected and historical results include but are not limited to:

- the failure to receive the required approval from Auxilium stockholders and applicable government and regulatory authorities (and the terms of those approvals)
- the risk that a condition to closing contemplated by the merger agreement may not be satisfied or waived;
- the ultimate outcome and results of integrating the operations of Endo and Auxilium, the ultimate outcome of Endo's operating strategy applied to Auxilium and the ultimate ability to realize synergies and the magnitude of such synergies;
- the effects of the business combination of Endo and Auxilium, including the combined company's future financial condition, operating results, strategy and plans;
- Endo's ability to achieve significant upside potential for shareholders by accelerating the growth of XI AFLEX and other products of the resultant combined company;
- Endo's ability to sustain and grow revenues and cash flow from operations in its markets and to maintain and grow its customer base, the need for innovation and the related capital expenditures and the unpredictable economic conditions in the United States and other markets;
- the impact of competition from other market participants;
- the development and commercialization of new products;
- the effects of governmental regulation on our business or potential business combination transaction;
- the availability and access, in general, of funds to meet ~~Endo's~~ obligations prior to or when they become due and to fund its operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets; and
- Endo's ability to comply with all covenants in its indentures and credit facilities, any violation of which, if not cured in a timely manner, could trigger a default of its other obligations under cross-default provisions.

All forward-looking statements attributable to Endo or Auxilium or any person acting on either of their behalf are expressly qualified in their entirety by this cautionary statement. These forward-looking statements speak only as of the date hereof. Neither Endo nor Auxilium assumes any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.



Our Journey to Date

- Restructured for efficiency and strengthened the organization
- Increased focus on core businesses to maximize organic growth potential
- Divested HealthTronics due to limited fit with company strategy
- Transformational transaction with Paladin Labs resulting in re-domicile to Ireland establishing a flexible international corporate structure
- Successfully completed and integrated multiple value creating acquisitions
- Advanced the pipeline across all businesses
- Met or exceeded all financial targets to date




- Aligns with Endo's strategy of pursuing accretive, value creating growth opportunities
- Enhances Endo's branded pharmaceutical business with the addition of Auxilium's leading men's healthcare products and development portfolio
- Accelerates growth of and maximizes value of Auxilium's products by leveraging strengths of combined company
 - *Enhance the long term organic growth for combined branded pharmaceutical business*
 - *Expand R&D capabilities and development programs*
- Generates significant synergy opportunities in addition to Auxilium's announced restructuring
- Creates company with enhanced financial flexibility, proven M&A platform and established corporate structure

Auxilium Snapshot

Ticker: NASDAQ "AUXL"
Headquarters: Chesterbrook, Pennsylvania
Founded: 1999
Headcount: ~480 employees

- Specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences
- Emerging leader in men's healthcare and has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas
- Broad range of first and second-line products across multiple indications with strong R&D capabilities and pipeline
- Portfolio of FDA-approved products in the urology, orthopedics and other areas in the U.S., and in select international markets



(1) -Reported Total Net Revenues for the 12-month period ended June 30, 2014

Combination Aligns with Endo's Strategic Direction

- Endo executing strategic plan to enhance shareholder value
 - Meeting or exceeding financial targets
 - Maximizing the growth potential of core businesses
 - Continued investment in de-risked R&D
 - Lean and efficient operating model
 - Pursuing accretive value creating M&A that delivers compelling financial returns and future organic growth options

- Value creating combination
 - Addition of Auxilium's XIAFLEX®, STENDRA® and other products complement Endo's branded pharmaceuticals portfolio
 - Opportunity for XIAFLEX® potential new indications supports long-term organic growth
 - Combined company will have broad range of therapeutic options in men's health
 - Enhanced operating efficiencies



Accelerating Organic Growth

- Auxilium's FDA-approved products in urology, orthopedics, and other areas are natural complements to men's health and pain products in Endo's branded pharmaceuticals portfolio
- Endo expects to optimize Auxilium's portfolio of products by leveraging scale, competencies and resources
 - Drive increased adoption and continued strong performance for Auxilium's XIAFLEX[®] and STENDRA[®]
 - Support development of XIAFLEX[®] potential new indications
 - Optimize Auxilium's broader portfolio
- Combined company will be well positioned to drive organic growth in branded pharmaceuticals business



Select Highlights of Complementary Product Portfolio

Men's Health / Urology	Orthopedics / Pain	Other Specialty
------------------------	--------------------	-----------------



AVEED
(testosterone undecanoate) injection 750 mg/3 mL

FORTESTA
(testosterone) Gel 1%
10 mg of testosterone per 0.5 g

VALSTAR
(valrubicin)
200 mg 5 mL Sterile Subcutaneous Implant (for intratumoral use)

VANTAS
(histrelin acetate) subcutaneous implant

opana^{ER}
(oxycodone HCl) 8 EXTENDED-RELEASE TABLETS
8mg / 2mg, 16mg / 2mg, 24mg / 2mg, 32mg / 2mg

Voltaren Gel
(diclofenac sodium topical gel) 1%

Sumavel[®] DosePro[®]
(sumatriptan injection)
Needle-free delivery system 6mg

Percocet[®]
(oxycodone and acetaminophen tablets, USP)

Frova[®]
Frovatriptan Succinate
2.5 mg Tablets

SUPPRELIN[®] LA
(histrelin acetate) subcutaneous implant



XIAFLEX[®]
chondroitin sulfate hydrochloride

STENDRA[®]
(tadalafil) tablets

TESTOPEL[®]
(testosterone pellets) 6

edex[®]
(alprostadil for injection)
10 mcg - 20 mcg - 40 mcg

Testim[®]
(testosterone gel) 1%

Testosterone Gel 1%
Authorized Generic

XIAFLEX[®]
chondroitin sulfate hydrochloride

Theo24[®]
theophylline extended-release tablets

Semprex-D Capsules
(carbamazepine and pseudoephedrine hydrochloride)



OSRON ErecAid[®]
alprostadil urethral suppository

STRIANT[®]
trastuzumab (Herceptin) 440 mg intravenous injection

dilatrate[®]-SR
(isosorbide dinitrate) sustained release capsules
40 mg

robaxin[®]-750
(methocarbamol) tablets, USP